06.11.2023
opracowała: dr n. med. Martyna Biała
na podstawie: Xiaoqiang Liu, i wsp.: Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial. Int. J. Infect. Dis., 2023;134: 53–62